The planned sale of France’s best-selling medical drug, Doliprane, to US investors has stirred controversy, with concerns over sovereignty and national security.
Amid debates over the impact of the sale, it’s emphasized that Doliprane, a widely recognized painkiller, holds a significant place in French healthcare.
The potential sale of a 50% stake has raised alarms among politicians, with fears of the loss of control over a vital medical asset.
‘Protect France’
Various political figures have expressed worries about the implications of such a sale, citing concerns about France’s ability to safeguard its health sector.
Government officials have highlighted the need to ensure that essential operations related to Doliprane remain within the country to secure supply and preserve jobs.
Despite assurances from the potential buyer about maintaining operations in France, tensions continue to rise over the future ownership of Doliprane.